NEW YORK (GenomeWeb News) — Soon after Illumina last week disclosed its plans to acquire Solexa for $600 million in stock, Illumina’s CEO spent the rest of the week explaining to investors and employees how the deal emerged, and how the two companies plan to integrate their technologies and businesses.
 
After the merger, expected to close by the end of next March, Solexa will become a sequencing business unit of Illumina. Solexa currently employs 175people and Illumina had 375staffers as of January.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.